Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has maintained its Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and raised the price target from $38 to $39.
September 19, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reaffirmed its Buy rating for 4D Molecular Therapeutics and increased the price target from $38 to $39, indicating a positive outlook.
The reaffirmation of a Buy rating and a slight increase in the price target by Chardan Capital suggests confidence in 4D Molecular Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100